Results 51 to 60 of about 81,297 (236)
Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [PDF]
Journal of Pharmacy & Pharmacognosy ResearchContext: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.
Nur Aini Hasan +4 more
doaj +1 more source
Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy
Advanced Science, EarlyView.Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu +6 more
wiley +1 more source
BMC Complementary Medicine and Therapies, 2023 Background Cardiovascular disease and cancer are the main causes of morbidity and mortality worldwide. Studies have shown that these two diseases may have some common risk factors.
Yu-qian Li +10 more
doaj +1 more source
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. [PDF]
, 2015 BackgroundImprovement in renal function and decreases in serum uric acid (SUA) have been reported following prolonged high-intensity statin (HMG-CoA reductase inhibitor) therapy.
Deedwania, Prakash C +4 more
core
Archives of Medicine and Health Sciences, 2017 Objective: Beneficial effects of statins on chronic obstructive pulmonary disease (COPD) have been projected in many retrospective studies, but prospective studies were lacking.
Manisha Bisht, Jagdish Rawat
doaj +1 more source
Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
Chinese Medical Journal, 2015 Objective: Statins are still underused for the prevention of cardiovascular disease (CVD) in China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and adverse events of atorvastatin, as well as on patient adherence.
Yi-Cong Ye +2 more
doaj +1 more source
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model [PDF]
, 2013 International audienceBackgroundProveblue®, a methylene blue dye that complies with European Pharmacopoeia and contains limited organic impurities and heavy metals of recognized toxicity, showed in vitro synergy against Plasmodium falciparum when ...
Briolant, Sébastien +3 more
core +3 more sources
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge. [PDF]
Fundam Clin PharmacolABSTRACT Background Statin‐induced liver injury is frequent and usually not severe. The aim of the present study was to describe the safety of statin rechallenge after atorvastatin‐induced liver injury because it is poorly documented. Methods Cases of liver injury involving atorvastatin were selected from the French pharmacovigilance database ...
Bertin B +5 more
europepmc +2 more sources